论文部分内容阅读
目的 探索早期应用1 3 1 I标记抗CEA单抗预防结肠腺癌肝转移的可行性。方法 在建立人结肠腺癌裸鼠肝转移后 ,于 15min、10、2 0d经尾静脉注射1 3 1 I标记抗CEA单抗 ;于放射免疫疗法后 4周和裸鼠死亡时 ,检查肝转移癌的数目、大小、瘤重、组织学和生存期。结果 早期治疗组的肝转移癌数目、大小和瘤重均明显减小 ,瘤结节内有明显坏死 ,生存期延长。结论 早期应用1 3 1 I标记抗CEA单抗能有效地抑制肝转移癌的形成
Objective To explore the feasibility of early application of 137I-labeled anti-CEA monoclonal antibody in preventing liver metastasis of colonic adenocarcinoma. Methods After hepatic metastasis of human colon adenocarcinoma nude mice was established,13 1 I-labeled anti-CEA McAb was injected via tail vein at 15 min, 10, and 20 d. Hepatic metastases were examined 4 weeks after radioimmunotherapy and when nude mice died. The number, size, weight, histology, and survival of the cancer. Results The number, size, and weight of hepatic metastases in the early treatment group were significantly reduced, with necrosis within the tumor nodules and prolonged survival. Conclusion Early application of 137I-labeled anti-CEA monoclonal antibody can effectively inhibit the formation of liver metastases